Rheumatic-Heart Disease Management Market by Type, Application & Region | Forecast 2023 to 2033

<p>The global <strong>Rheumatic-Heart Disease Management market size </strong>is expected to be valued at <strong>US$ 1.31 Billion </strong>in 2023. With the continuous improvements in drugs and biotechnology, the overall <strong>demand for Rheumatic-Heart Disease Management </strong>is projected to grow at a CAGR of <strong>4.5%</strong> between 2023 and 2033, totaling around <strong>US$ 2.04 Billion</strong> by 2033.</p><table><tbody><tr><th scope='row'>Data Points</th><td>Key Statistics</td></tr><tr><th scope='row'>Rheumatic-Heart Disease Management Market Value 2023</th><td>US$ 1.31 Billion</td></tr><tr><th scope='row'>Rheumatic-Heart Disease Management Market Projected Value (2033)</th><td>US$ 2.04 Billion</td></tr><tr><th scope='row'>Rheumatic-Heart Disease Management Market CAGR (2023 to 2033)</th><td>4.5%</td></tr></tbody></table><p>Report Scope</p><table><tbody><tr><th scope='row'>Report Attribute</th><td>Details</td></tr><tr><th scope='row'>Growth Rate</th><td>CAGR of 4.5% from 2023 to 2033</td></tr><tr><th scope='row'>Market Value in 2023</th><td>US$ 1.31 Billion</td></tr><tr><th scope='row'>Market Value in 2033</th><td>US$ 2.04 Billion</td></tr><tr><th scope='row'>Base Year for Estimation</th><td>2022</td></tr><tr><th scope='row'>Historical Data</th><td>2018 to 2022</td></tr><tr><th scope='row'>Forecast Period</th><td>2023 to 2033</td></tr><tr><th scope='row'>Quantitative Units</th><td>Revenue in US$ Billion and CAGR from 2023 to 2033</td></tr><tr><th scope='row'>Report Coverage</th><td>Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis</td></tr><tr><th scope='row'>Segments Covered</th><td><ul><li>Type</li><li>Application</li><li>Region</li></ul></td></tr><tr><th scope='row'>Regions Covered</th><td><ul><li>North America</li><li>Europe</li><li>Europe</li><li>Latin America</li><li>Middle East &amp; Africa</li></ul></td></tr><tr><th scope='row'>Key Countries Profiled</th><td><ul><li>USA</li><li>Canada</li><li>Brazil</li><li>Mexico</li><li>Germany</li><li>United Kingdom</li><li>France</li><li>Spain</li><li>Italy</li><li>China</li><li>Japan</li><li>South Korea</li><li>Malaysia</li><li>Singapore</li><li>Australia</li><li>New Zealand</li><li>GCC Countries</li><li>South Africa</li><li>Israel</li></ul></td></tr><tr><th scope='row'>Key Companies Profiled</th><td><ul><li>F. Hoffmann-La Roche Ltd.</li><li>Mylan N.V.</li><li>Teva Pharmaceutical Industries Ltd.</li><li>Sanofi</li><li>Pfizer Inc.</li><li>GlaxoSmithKline plc.</li><li>Novartis AG</li><li>Bayer AG</li><li>Eli Lilly and Company</li><li>Merck &amp; Co., Inc.</li><li>Allergan</li><li>AstraZeneca</li><li>AbbVie Inc.</li><li>Johnson &amp; Johnson Private Limited</li><li>Cipla Inc.</li><li>Abbott</li><li>Merck KGaA</li><li>Sun Pharmaceutical Industries Ltd.</li><li>Aurobindo Pharma</li><li>Dr. Reddy&rsquo;s Laboratories Ltd.</li><li>Glenmark Pharmaceuticals Limited</li><li>Amneal Pharmaceuticals LLC.</li><li>Bayer AG</li></ul></td></tr></tbody></table>

<p>全球风湿性心脏病管理市场规模预计在2023年将达到13.1亿美元。随着药物及生物技术的持续进步，风湿性心脏病管理领域的整体需求预计将在2023年至2033年期间以4.5%的复合年增长率增长，至2033年将达到约20.4亿美元。</p><table><tbody><tr><th scope='row'>数据点</th><td>关键统计数据</td></tr><tr><th scope='row'>风湿性心脏病管理市场规模（2023年）</th><td>13.1亿美元</td></tr><tr><th scope='row'>风湿性心脏病管理市场规模预测值（2033年）</th><td>20.4亿美元</td></tr><tr><th scope='row'>风湿性心脏病管理市场规模复合年增长率（2023年至2033年）</th><td>4.5%</td></tr></tbody></table><p>报告范围</p><table><tbody><tr><th scope='row'>报告属性</th><td>详细信息</td></tr><tr><th scope='row'>增长率</th><td>2023年至2033年的复合年增长率为4.5%</td></tr><tr><th scope='row'>2023年市场规模</th><td>13.1亿美元</td></tr><tr><th scope='row'>2033年市场规模</th><td>20.4亿美元</td></tr><tr><th scope='row'>估算的基准年</th><td>2022年</td></tr><tr><th scope='row'>历史数据</th><td>2018年至2022年</td></tr><tr><th scope='row'>预测期</th><td>2023年至2033年</td></tr><tr><th scope='row'>定量单位</th><td>以亿美元计的收入和2023年至2033年的复合年增长率</td></tr><tr><th scope='row'>报告覆盖范围</th><td>收入预测、公司排名、竞争格局、增长因素、趋势和定价分析</td></tr><tr><th scope='row'>涵盖的细分市场</th><td><ul><li>类型</li><li>应用</li><li>地区</li></ul></td></tr><tr><th scope='row'>涵盖的地区</th><td><ul><li>北美</li><li>欧洲</li><li>欧洲</li><li>拉丁美洲</li><li>中东及非洲</li></ul></td></tr><tr><th scope='row'>主要国家概况</th><td><ul><li>美国</li><li>加拿大</li><li>巴西</li><li>墨西哥</li><li>德国</li><li>英国</li><li>法国</li><li>西班牙</li><li>意大利</li><li>中国</li><li>日本</li><li>韩国</li><li>马来西亚</li><li>新加坡</li><li>澳大利亚</li><li>新西兰</li><li>海湾合作委员会国家</li><li>南非</li><li>以色列</li></ul></td></tr><tr><th scope='row'>主要公司概况</th><td><ul><li>F. Hoffmann-La Roche Ltd.</li><li>Mylan N.V.</li><li>Teva Pharmaceutical Industries Ltd.</li><li>Sanofi</li><li>Pfizer Inc.</li><li>GlaxoSmithKline plc.</li><li>Novartis AG</li><li>Bayer AG</li><li>Eli Lilly and Company</li><li>Merck & Co., Inc.</li><li>Allergan</li><li>AstraZeneca</li><li>AbbVie Inc.</li><li>Johnson &amp; Johnson Private Limited</li><li>Cipla Inc.</li><li>Abbott</li><li>Merck KGaA</li><li>Sun Pharmaceutical Industries Ltd.</li><li>Aurobindo Pharma</li><li>Dr. Reddy&rsquo;s Laboratories Ltd.</li><li>Glenmark Pharmaceuticals Limited</li><li>Amneal Pharmaceuticals LLC.</li><li>Bayer AG</li></ul></td></tr></tbody></table>